These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 22134373)

  • 41. Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations.
    Müller T
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1015-24. PubMed ID: 23642267
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
    Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice.
    Luthra PM; Prakash A; Barodia SK; Kumari R; Mishra CB; Kumar JB
    Neurosci Lett; 2009 Oct; 463(3):215-8. PubMed ID: 19654038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can adenosine A
    Jenner P; Mori A; Kanda T
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S28-S36. PubMed ID: 33349577
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adenosine A(2A) receptors in nonlocomotor features of Parkinson's disease: introduction.
    Ongini E
    Neurology; 2003 Dec; 61(11 Suppl 6):S72-3. PubMed ID: 14663015
    [No Abstract]   [Full Text] [Related]  

  • 47. Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.
    Kanda T; Uchida S
    Int Rev Neurobiol; 2014; 119():127-50. PubMed ID: 25175964
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recent progress in the discovery of adenosine A(2A) receptor antagonists for the treatment of Parkinson's disease.
    Shah U; Hodgson R
    Curr Opin Drug Discov Devel; 2010 Jul; 13(4):466-80. PubMed ID: 20597030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
    Fox SH; Chuang R; Brotchie JM
    Prog Brain Res; 2008; 172():479-94. PubMed ID: 18772047
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Huang YX; Luo WF; Li D; Hu WD; Liu CF
    Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
    Pinna A; Volpini R; Cristalli G; Morelli M
    Eur J Pharmacol; 2005 Apr; 512(2-3):157-64. PubMed ID: 15840400
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antagonists of the human A(2A) receptor. Part 6: Further optimization of pyrimidine-4-carboxamides.
    Gillespie RJ; Bamford SJ; Clay A; Gaur S; Haymes T; Jackson PS; Jordan AM; Klenke B; Leonardi S; Liu J; Mansell HL; Ng S; Saadi M; Simmonite H; Stratton GC; Todd RS; Williamson DS; Yule IA
    Bioorg Med Chem; 2009 Sep; 17(18):6590-605. PubMed ID: 19695884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A(2A)/D(2) receptor heteromerization in a model of Parkinson's disease. Focus on striatal aminoacidergic signaling.
    Ferraro L; Beggiato S; Tomasini MC; Fuxe K; Antonelli T; Tanganelli S
    Brain Res; 2012 Oct; 1476():96-107. PubMed ID: 22370145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T; Jackson MJ; Smith LA; Pearce RK; Nakamura J; Kase H; Kuwana Y; Jenner P
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?
    Huot P; Fox SH; Newman-Tancredi A; Brotchie JM
    J Pharmacol Exp Ther; 2011 Oct; 339(1):2-8. PubMed ID: 21784889
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice.
    Marcellino D; Lindqvist E; Schneider M; Müller CE; Fuxe K; Olson L; Galter D
    Neurobiol Dis; 2010 Nov; 40(2):460-6. PubMed ID: 20656029
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effects of the adenosine A2A receptor antagonist on cognitive dysfunction in Parkinson's disease.
    Uchida S; Kadowaki-Horita T; Kanda T
    Int Rev Neurobiol; 2014; 119():169-89. PubMed ID: 25175966
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease.
    Simola N; Fenu S; Baraldi PG; Tabrizi MA; Morelli M
    J Neurol Sci; 2006 Oct; 248(1-2):48-52. PubMed ID: 16780890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Receptor-receptor interactions within receptor mosaics. Impact on neuropsychopharmacology.
    Fuxe K; Marcellino D; Rivera A; Diaz-Cabiale Z; Filip M; Gago B; Roberts DC; Langel U; Genedani S; Ferraro L; de la Calle A; Narvaez J; Tanganelli S; Woods A; Agnati LF
    Brain Res Rev; 2008 Aug; 58(2):415-52. PubMed ID: 18222544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.